Avdoralimab

艾朵利单抗

Report date: 2026/03/30 20:02:02

Base Information

Drug NameAvdoralimab
Drug Alias NameNNC-0215-0384NN-8210IPH-5401Anti-C5aR-215
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionC5a anaphylatoxin chemotactic receptor antagonists
TargetsC5a anaphylatoxin chemotactic receptor
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Solid tumoursInflammation +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPolandRussian Federation +[6] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNovo Nordisk A/S
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovo Nordisk A/SInnate Pharma
Active IndicationsN/A
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Solid tumoursInflammation +[4] 

Other Information

ATC CodeN/A
Related LinksN/A